Increase in tiagabine serum concentration with coadministration of gemfibrozil

Aaron H. Burstein, Eilis Boudreau, William H. Theodore

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVE: To report a case of possible acute tiagabine toxicity secondary to administration of gemfibrozil. CASE SUMMARY: A 39-year-old male was taking tiagabine 16 mg orally 3 times per day and carbamazepine 500 mg orally twice per day for complex partial seizures secondary to mesial temporal sclerosis. He was found to have type IV hypertriglyceridemia and was prescribed gemfibrozil. Because he reported severe confusion and altered consciousness shortly after a single 600-mg dose of gemfibrozil, he was admitted for controlled challenge with that drug. A single 300-mg dose of gemfibrozil resulted in lightheadedness and led to a 59% and 75% increase in total tiagabine serum concentrations at 2 and 5 hours, respectively, without significant change in baseline carbamazepine concentrations. DISCUSSION: This is the first report of an interaction between the widely used antihyperlipidemic drug gemfibrozil and tiagabine. Since tiagabine, which was originally developed as an antiepileptic medication, is now being used widely for a variety of other indications such as anxiety and depression, there is an increased risk for clinically significant interactions with gemfibrozil. CONCLUSIONS: Increased total and unbound tiagabine concentrations following a single 300-mg dose of gemfibrozil and reproduction of clinical symptoms with gemfibrozil rechallenge suggests the toxicity our patient experienced was due to a pharmacokinetic drug interaction. Use of the Horn Drug Interaction Probability Scale showed a probable interaction between gemfibrozil and tiagabine.

Original languageEnglish (US)
Pages (from-to)379-382
Number of pages4
JournalAnnals of Pharmacotherapy
Volume43
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Gemfibrozil
Serum
Carbamazepine
Drug Interactions
Hypolipidemic Agents
tiagabine
Confusion
Hypertriglyceridemia
Dizziness
Sclerosis
Horns
Consciousness
Pharmaceutical Preparations
Anticonvulsants
Reproduction
Seizures
Anxiety
Pharmacokinetics
Depression

Keywords

  • Gemfibrozil
  • Interaction
  • Pharmacokinetics
  • Tiagabine

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Increase in tiagabine serum concentration with coadministration of gemfibrozil. / Burstein, Aaron H.; Boudreau, Eilis; Theodore, William H.

In: Annals of Pharmacotherapy, Vol. 43, No. 2, 02.2009, p. 379-382.

Research output: Contribution to journalArticle

Burstein, Aaron H. ; Boudreau, Eilis ; Theodore, William H. / Increase in tiagabine serum concentration with coadministration of gemfibrozil. In: Annals of Pharmacotherapy. 2009 ; Vol. 43, No. 2. pp. 379-382.
@article{1cebd2a069ff44c3b0ce8060ebe29ada,
title = "Increase in tiagabine serum concentration with coadministration of gemfibrozil",
abstract = "OBJECTIVE: To report a case of possible acute tiagabine toxicity secondary to administration of gemfibrozil. CASE SUMMARY: A 39-year-old male was taking tiagabine 16 mg orally 3 times per day and carbamazepine 500 mg orally twice per day for complex partial seizures secondary to mesial temporal sclerosis. He was found to have type IV hypertriglyceridemia and was prescribed gemfibrozil. Because he reported severe confusion and altered consciousness shortly after a single 600-mg dose of gemfibrozil, he was admitted for controlled challenge with that drug. A single 300-mg dose of gemfibrozil resulted in lightheadedness and led to a 59{\%} and 75{\%} increase in total tiagabine serum concentrations at 2 and 5 hours, respectively, without significant change in baseline carbamazepine concentrations. DISCUSSION: This is the first report of an interaction between the widely used antihyperlipidemic drug gemfibrozil and tiagabine. Since tiagabine, which was originally developed as an antiepileptic medication, is now being used widely for a variety of other indications such as anxiety and depression, there is an increased risk for clinically significant interactions with gemfibrozil. CONCLUSIONS: Increased total and unbound tiagabine concentrations following a single 300-mg dose of gemfibrozil and reproduction of clinical symptoms with gemfibrozil rechallenge suggests the toxicity our patient experienced was due to a pharmacokinetic drug interaction. Use of the Horn Drug Interaction Probability Scale showed a probable interaction between gemfibrozil and tiagabine.",
keywords = "Gemfibrozil, Interaction, Pharmacokinetics, Tiagabine",
author = "Burstein, {Aaron H.} and Eilis Boudreau and Theodore, {William H.}",
year = "2009",
month = "2",
doi = "10.1345/aph.1L080",
language = "English (US)",
volume = "43",
pages = "379--382",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "2",

}

TY - JOUR

T1 - Increase in tiagabine serum concentration with coadministration of gemfibrozil

AU - Burstein, Aaron H.

AU - Boudreau, Eilis

AU - Theodore, William H.

PY - 2009/2

Y1 - 2009/2

N2 - OBJECTIVE: To report a case of possible acute tiagabine toxicity secondary to administration of gemfibrozil. CASE SUMMARY: A 39-year-old male was taking tiagabine 16 mg orally 3 times per day and carbamazepine 500 mg orally twice per day for complex partial seizures secondary to mesial temporal sclerosis. He was found to have type IV hypertriglyceridemia and was prescribed gemfibrozil. Because he reported severe confusion and altered consciousness shortly after a single 600-mg dose of gemfibrozil, he was admitted for controlled challenge with that drug. A single 300-mg dose of gemfibrozil resulted in lightheadedness and led to a 59% and 75% increase in total tiagabine serum concentrations at 2 and 5 hours, respectively, without significant change in baseline carbamazepine concentrations. DISCUSSION: This is the first report of an interaction between the widely used antihyperlipidemic drug gemfibrozil and tiagabine. Since tiagabine, which was originally developed as an antiepileptic medication, is now being used widely for a variety of other indications such as anxiety and depression, there is an increased risk for clinically significant interactions with gemfibrozil. CONCLUSIONS: Increased total and unbound tiagabine concentrations following a single 300-mg dose of gemfibrozil and reproduction of clinical symptoms with gemfibrozil rechallenge suggests the toxicity our patient experienced was due to a pharmacokinetic drug interaction. Use of the Horn Drug Interaction Probability Scale showed a probable interaction between gemfibrozil and tiagabine.

AB - OBJECTIVE: To report a case of possible acute tiagabine toxicity secondary to administration of gemfibrozil. CASE SUMMARY: A 39-year-old male was taking tiagabine 16 mg orally 3 times per day and carbamazepine 500 mg orally twice per day for complex partial seizures secondary to mesial temporal sclerosis. He was found to have type IV hypertriglyceridemia and was prescribed gemfibrozil. Because he reported severe confusion and altered consciousness shortly after a single 600-mg dose of gemfibrozil, he was admitted for controlled challenge with that drug. A single 300-mg dose of gemfibrozil resulted in lightheadedness and led to a 59% and 75% increase in total tiagabine serum concentrations at 2 and 5 hours, respectively, without significant change in baseline carbamazepine concentrations. DISCUSSION: This is the first report of an interaction between the widely used antihyperlipidemic drug gemfibrozil and tiagabine. Since tiagabine, which was originally developed as an antiepileptic medication, is now being used widely for a variety of other indications such as anxiety and depression, there is an increased risk for clinically significant interactions with gemfibrozil. CONCLUSIONS: Increased total and unbound tiagabine concentrations following a single 300-mg dose of gemfibrozil and reproduction of clinical symptoms with gemfibrozil rechallenge suggests the toxicity our patient experienced was due to a pharmacokinetic drug interaction. Use of the Horn Drug Interaction Probability Scale showed a probable interaction between gemfibrozil and tiagabine.

KW - Gemfibrozil

KW - Interaction

KW - Pharmacokinetics

KW - Tiagabine

UR - http://www.scopus.com/inward/record.url?scp=60349129498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60349129498&partnerID=8YFLogxK

U2 - 10.1345/aph.1L080

DO - 10.1345/aph.1L080

M3 - Article

C2 - 19193595

AN - SCOPUS:60349129498

VL - 43

SP - 379

EP - 382

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 2

ER -